Related Experiment Videos
Conventional vs. newer antipsychotics in elderly patients
D V Jeste1, E Rockwell, M J Harris
1Department of Psychiatry, University of California, San Diego, USA. Dilip_Jeste@GP-Post.ucsd.edu
Summary
Elderly patients treated with conventional antipsychotics face a high annual risk of tardive dyskinesia (TD). Newer antipsychotics may offer a safer alternative with fewer side effects for managing schizophrenia and dementia symptoms.
Area of Science:
- Geriatric Psychiatry
- Pharmacology
- Neurology
Background:
- Elderly patients with schizophrenia and dementia often require antipsychotic medication.
- Conventional neuroleptics have limited efficacy for negative symptoms and significant side effect profiles in the elderly.
- Tardive dyskinesia (TD) is a serious concern with long-term antipsychotic use.
Purpose of the Study:
- To evaluate the risk of tardive dyskinesia (TD) in elderly outpatients treated with conventional neuroleptics.
- To compare the efficacy and side effect profiles of conventional versus newer antipsychotics in elderly populations.
- To inform treatment guidelines for antipsychotic use in elderly patients with schizophrenia and dementia.
Main Methods:
- Retrospective analysis of cumulative annual incidence of TD.
- Review of treatment outcomes and side effects associated with conventional and newer antipsychotics.
- Assessment of symptom improvement (positive and negative) and cognitive effects.
Main Results:
- A 29% cumulative annual incidence of TD was observed in middle-aged and elderly outpatients on conventional neuroleptics.
- Newer antipsychotics show a lower likelihood of extrapyramidal symptoms and potentially reduced TD risk.
- Newer agents demonstrate effectiveness for positive and negative symptoms, with possible cognitive benefits.
Conclusions:
- Conventional antipsychotics carry a substantial risk of TD in elderly patients, even at low doses.
- Newer antipsychotics may represent a safer and more effective treatment option for elderly patients with schizophrenia and agitation.
- Careful dosing and consideration of newer agents are crucial for managing antipsychotic treatment in geriatric populations.